Lenvatinib launched for kidney cancer

Kisplyx (lenvatinib) is licensed in combination with everolimus for the treatment of adults with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Lenvatinib is a potent inhibitor of multiple tyrosine kinases: VEGF receptors 1, 2 and 3, platelet-derived growth factor and fibroblast growth factor receptors, KIT and RET. It is already available as Lenvima to treat thyroid cancer.

Lenvatinib in combination with everolimus was shown to significantly improve progression-free survival compared with everolimus monotherapy in a randomised phase II trial in patients with advanced or metastatic renal cell carcinoma that had progressed despite treatment with a VEGF-targeted therapy (n=153).

Median progression-free survival was 14.6 months (95% CI 5.9—20.1) in the lenvatinib plus everolimus group compared with 5.5 months (95% CI 3.5—7.1) in the everolimus monotherapy group (hazard ratio 0.40, 95% CI 0.240.68; p=0.0005).

The most common adverse events in the combination group were diarrhoea and fatigue/asthenia.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.